Translating molecular advances in fragile X syndrome into therapy: a review.

Détails

ID Serval
serval:BIB_DAD145FB477A
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Translating molecular advances in fragile X syndrome into therapy: a review.
Périodique
Journal of Clinical Psychiatry
Auteur(s)
Hagerman R.J., Des-Portes V., Gasparini F., Jacquemont S., Gomez-Mancilla B.
ISSN
1555-2101 (Electronic)
ISSN-L
0160-6689
Statut éditorial
Publié
Date de publication
2014
Peer-reviewed
Oui
Volume
75
Numéro
4
Pages
e294-e307
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review Publication Status: ppublish Document Type: Review PDF : Review Article
Résumé
Fragile X syndrome is an inherited disease with cognitive, behavioral, and neurologic manifestations, resulting from a single genetic mutation. A variety of treatments that target individual symptoms of fragile X syndrome are currently utilized with limited efficacy. Research in animal models has resulted in the development of potential novel pharmacologic treatments that target the underlying molecular defect in fragile X syndrome, rather than the resultant symptoms. This review describes recent advances in our understanding of the molecular basis of fragile X syndrome and summarizes the ongoing clinical research programs.
Mots-clé
Animals, Biomedical Research, Fragile X Mental Retardation Protein/genetics, Fragile X Syndrome/drug therapy, Fragile X Syndrome/etiology, Humans, Mice, Mice, Knockout/genetics, Receptor, Metabotropic Glutamate 5/drug effects, Receptor, Metabotropic Glutamate 5/genetics, Receptors, GABA/drug effects, Receptors, GABA/metabolism
Pubmed
Web of science
Création de la notice
28/06/2014 16:16
Dernière modification de la notice
03/03/2018 21:55
Données d'usage